Traws Pharma Inc (TRAW) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $2.6M

TRAW ranks #7186 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

34 institutions disclose a position in TRAW, but none treat it as a major bet — even Ally Bridge Group, its most concentrated holder, allocates just 0.6% of its own portfolio to it.

ADAR1 Capital Management, LLC has added to its TRAW position for two straight quarters, increasing it by $329.6K to reach $504.1K today.

UBS Group AG has trimmed its TRAW position for two straight quarters, cutting it by $5.8K while still holding $2.9K.

TRAW is down 7.5% today, but institutions show net buying of $2.6M this quarter — a divergence between today's price move and the underlying institutional flow.

TRAW reported a net loss of $21.6M over the trailing twelve months.

• Not yet profitable — net loss of $21.6M over the trailing twelve months
• Revenue grew 1134.5% year over year
• Net income declined year over year, from -$17.8M to -$21.6M
• Operating cash flow was negative, using $18.2M in cash
• Current ratio of 0.72x — below the conventional 1.5x liquidity buffer